Zerviate®
cetirizine 0.24% · ophthalmic solution
Allergy
Approved uses
Ocular itching associated with allergic conjunctivitis
1 drop in each affected eye BID, approximately 8 hours apart
Itch relief begins within 15 minutes of dosing and lasts about 8 hours.
Contraindications
None.
Ophthalmic solution, 0.24% (2.4 mg/mL), 30 single-use 0.2 mL containers
Topical histamine-1 (H1) receptor antagonist that blocks histamine-mediated ocular itching. In vitro binding shows no measurable affinity for receptors other than H1, with negligible anticholinergic and antiserotonergic activity in animal models.
Warnings & Precautions
- Lens wear: Remove lenses before instillation and reinsert 10 minutes afterward; the benzalkonium chloride preservative may be absorbed by soft lenses. Lenses should not be worn while the eye is red.
- Lens-related irritation: Not for treating eye irritation caused by contact lens wear.
- Contamination of tip and solution: Do not touch the eyelids or surrounding areas with the tip of the single-use container, to avoid injury to the eye and to prevent contaminating the tip and solution; discard the single-use container after using in each eye.
Common Side Effects
In seven clinical trials (cetirizine N=511, vehicle N=329), the most commonly reported adverse reactions were ocular hyperemia, instillation site pain, and visual acuity reduced, which occurred in approximately 1-7% of patients treated with either cetirizine or vehicle.
Pregnancy: No adequate, well-controlled studies in pregnant women; not teratogenic in mice, rats or rabbits at oral doses approximately 1300 to 7400 times the maximum recommended human ophthalmic dose. Use only if the potential benefit justifies the potential fetal risk.
Lactation: Oral cetirizine has been reported to be excreted in human breast milk; whether topical ocular dosing produces detectable milk levels is unknown, and there are no data on effects on the breastfed infant or on milk production.
Safety and effectiveness established in patients 2 years and older.